A Phase 1, Open-Label Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
Latest Information Update: 06 May 2025
At a glance
- Drugs SYNCAR-001 (Primary) ; SYNCAR-001 (Primary)
- Indications Diffuse scleroderma; Lupus nephritis; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Synthekine
Most Recent Events
- 27 Apr 2025 Planned initiation date (estimated date of first patient enrollment) changed from 1 Mar 2025 to 1 Apr 2025.
- 03 Mar 2025 Planned number of patients changed from 42 to 48.
- 16 Jan 2025 Planned initiation date changed from 1 Dec 2024 to 1 Mar 2025.